Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| P040421 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Assistance Publique - Hôpitaux de Paris | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will compare, in adults with septic shock, the safety and efficacy of a combination of moderate doses of corticosteroids and intensive insulin therapy to that of moderate doses of corticosteroids. In addition, this study will compare the efficacy and safety of hydrocortisone alone versus hydrocortisone plus fludrocortisone
Objectives:
Comparison, in patients with septic shock, of efficacy and safety of the combination of moderate doses of corticosteroids and intensive insulin therapy to that of moderate doses of corticosteroids; and of efficacy and safety of hydrocortisone alone versus hydrocortisone plus fludrocortisone Methods
Study design :
This is a multicenter, prospective, randomised trial on parallel groups
Study treatments :
Experimental arm A:
A1=50 mg iv every 6 hours of hydrocortisone (hemisuccinate), 50µg through the nasogastric tube of 9 alpha fludrocortisone, for 7 days AND strict control of blood glucose levels with a target of 4,4 to 6 mmol/L using continuous iv infusion of insulin up to intensive care unit discharge.
A2=50 mg iv every 6 hours of hydrocortisone (hemisuccinate) for 7 days AND strict control of blood glucose levels with a target of 4,4 to 6 mmol/L using continuous iv infusion of insulin up to intensive care unit discharge.
Control arm B:
B1:50 mg iv every 6 hours of hydrocortisone (hemisuccinate), 50µg through the nasogastric tube of 9 alpha fludrocortisone, for 7 days.
B2:50 mg iv every 6 hours of hydrocortisone (hemisuccinate)for 7 days. Study Primary outcome : In-hospital mortality
Sample size calculation :
The expected in-hospital mortality rate in the control group is 50%. To detect an absolute reduction in in-hospital mortality rate of 12.5 %, that is 37.5% in the experimental arm versus 50% in the control arm, and considering risk alpha of 0,05 and a risk beta of 0,20, 254 patients per treatment arms are needed, for a total of 508 patients.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Active Comparator | Hydrocortisone and convention glycemic control |
|
| 2 | Experimental | Hydrocortisone and fludrocortisone and conventional glucose control |
|
| 3 | Experimental | Hydrocortisone and intensive insulin therapy |
|
| 4 | Experimental | hydrocortisone, fludrocortisone and intensive insulin therapy |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| recombinant human insulin | Drug | intensive insulin therapy as a continuous infusion to maintain blood glucose levels between 4 and 6 mmol/l |
|
| Measure | Description | Time Frame |
|---|---|---|
| In-hospital mortality | Day 180 |
| Measure | Description | Time Frame |
|---|---|---|
| Secondary outcomes : | Day 180 | |
| 90-day and 180-day mortality. | Day 180 | |
| Duration of life-supporting treatments (i.e. vasopressors and mechanical ventilation) |
Not provided
Inclusion Criteria:
Patients admitted in intensive care units for septic shock and meeting all following criteria
Exclusion Criteria:
One of the following :
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Djillali annane, MD, PhD | Assistance Publique Hôpitaux de Paris - University of Versailles | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hôpital Avicenne | Bobigny | France | ||||
| Hôpital Jean Verdier |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 20103758 | Result | COIITSS Study Investigators; Annane D, Cariou A, Maxime V, Azoulay E, D'honneur G, Timsit JF, Cohen Y, Wolf M, Fartoukh M, Adrie C, Santre C, Bollaert PE, Mathonet A, Amathieu R, Tabah A, Clec'h C, Mayaux J, Lejeune J, Chevret S. Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA. 2010 Jan 27;303(4):341-8. doi: 10.1001/jama.2010.2. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012772 | Shock, Septic |
| D000309 | Adrenal Insufficiency |
| ID | Term |
|---|---|
| D018805 | Sepsis |
| D007239 | Infections |
| D018746 | Systemic Inflammatory Response Syndrome |
| D007249 | Inflammation |
Not provided
Not provided
| ID | Term |
|---|---|
| D006854 | Hydrocortisone |
| D005438 | Fludrocortisone |
| ID | Term |
|---|---|
| D011282 | Pregnenediones |
| D011283 | Pregnenes |
| D011278 | Pregnanes |
| D013256 | Steroids |
| D000072473 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| hydrocortisone | Drug | 50 mg as iv bolus every 6 hours for 7 days |
|
| fludrocortisone | Drug | 50 µg once a day via a nasogastric tube for seven days |
|
| Hydrocortisone | Drug | hydrocortisone 50mg q6 for 7 days |
|
| Day 180 |
| Time to resolve multiple organ dysfunction, i.e. to obtain a SOFA score < 8 | Day 180 |
| Hospital length of stay. | Day 180 |
| Number of hypoglycaemic events (blood glucose < 4 mmol/l) during insulin infusion | Day 180 |
| Muscle weakness at discharge from intensive care unit, 90-day and 180-day | Day 180 |
| Post traumatic stress disorders | Day 180 |
| Bondy |
| France |
| CHU Grenoble | Grenoble | France |
| Hôpital central | Nancy | France |
| Hôpital Saint Louis | Paris | 75 | France |
| Hôpital Bichat Claude Bernard | Paris | France |
| hôpital Cochin | Paris | France |
| Hôpital Delafontaine | Saint-Denis | 93 | France |
| D010335 |
| Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012769 | Shock |
| D000307 | Adrenal Gland Diseases |
| D004700 | Endocrine System Diseases |
| Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D015062 | 11-Hydroxycorticosteroids |
| D006889 | Hydroxycorticosteroids |
| D000305 | Adrenal Cortex Hormones |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
| D015065 | 17-Hydroxycorticosteroids |